Abstract Favipiravir (T-705; 6-fluoro-3-hydroxy-2-pyrazinecarboxamide) is an anti-viral agent
that selectively and potently inhibits the RNA-dependent RNA polymerase (RdRp) of RNA …

Influenza virus polymerase inhibitors in clinical developmen... : Current Opinion in Infectious
Diseases Influenza virus polymerase inhibitors in clinical development : Current Opinion in …

Abstract Favipiravir (T-705; 6-fluoro-3-hydroxy-2-pyrazinecarboxamide) is an antiviral drug
that selectively inhibits the RNA-dependent RNA polymerase of influenza virus. It is …

H7N9 low pathogenic influenza viruses emerged in China in 2013 and mutated to highly
pathogenic strains in 2017, resulting in human infections and disease in chickens. To control …

Background The first identified cases of avian influenza A (H7N9) virus infection in humans
occurred in China during February and March 2013. We analyzed data obtained from field …

The recent emergence of a novel avian A/H 7 N 9 influenza virus in poultry and humans in C
hina, as well as laboratory studies on adaptation and transmission of avian A/H 5 N 1 …

Influenza A virions possess two surface glycoproteins—the hemagglutinin (HA) and
neuraminidase (NA)—which exert opposite functions. HA attaches virions to cells by binding …

Certain low pathogenic avian influenza viruses can mutate to highly pathogenic viruses
when they circulate in domestic poultry, at which point they can cause devastating poultry …

Pathogenic H7N9 avian influenza viruses continue to represent a public health concern, and
several candidate vaccines are currently being developed. It is vital to assess if protective …

H7N9 influenza viruses were first isolated in 2013 and continue to cause human infections.
H7N9 infections represent an ongoing public health threat that has resulted in 1344 cases …